Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mutagenesis sensitizes murine models of triple negative breast cancer to immunotherapy

ABSTRACT: This study identifies mechanisms of response to immune checkpoint inhibition in mouse models of triple negative breast cancer.

ORGANISM(S): Mus musculus

PROVIDER: GSE136206 | GEO | 2019/11/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Mutagenesis sensitizes murine models of triple negative breast cancer to immunotherapy

Project description:Mutagenesis sensitizes murine models of triple negative breast cancer to immunotherapy

| PRJNA561596 | ENA

Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy

Project description:Breast cancer is the most common cancer diagnosis in women. Clinical studies with triple-negative breast cancer (TNBC) are encouraging for immunotherapy combined with chemotherapy (aPD-1 with paclitaxel and/or carboplatin). However, additional clinical advances may be pursued more rapidly with assistance from preclinical TNBC models including syngeneic mammary tumor cell lines. Here, we report two mammary tumor cell lines that exhibit differential responsiveness to immunotherapy in vivo. Spontaneous mammary tumors from C57BL/6J MMTV-Cre Trp53fl/+ animals were passaged serially in cell culture and in vivo in the mammary fat pad of fully wildtype animals. The resulting lines, MM001i and MM008i, lost Trp53 and formed 1000 mm3 tumors in the mammary fat pad within 21-28 days. Despite originating from the same genetic background, these lines exhibit differential responses to immunotherapy. For aPD-1 therapy, MM001i is poorly responsive and MM008i is strongly responsive with near-complete tumor regression. In comparison, both MM001i and MM008i respond rapidly to aCTLA-4 therapy. Both models express unique tumor antigens as evidenced by immunity to subsequent engraftments. Primary MM008i tumors exhibit greater T cell infiltration, and CD8-positive T lymphocytes are required for aPD-1 responses. These TNBC models are promising for further mechanistic studies and testing future single and combinatorial therapies.

2026-01-30 | GSE305800 | GEO

Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer [ATAC-seq]

Project description:Immune checkpoint inhibitors combined with chemotherapy represent a promising treatment option in triple-negative breast cancer (TNBC). However, response rates are still relatively low necessitating the design of novel therapeutic strategies to improve clinical outcomes. Here, we describe a triple combination of anti-PDL-1 immune checkpoint blockade, epigenetic modulation thorough BET bromodomain inhibition, and chemotherapy with paclitaxel that effectively inhibits both primary and metastatic tumor growth in two different syngeneic murine breast cancer models. Detailed cellular and molecular profiling of tumors from single and combination treatment arms revealed increased T and B cell infiltration and macrophage reprogramming from M1 to a M2 phenotype in mice treated with triple combination.

2023-08-15 | GSE229426 | GEO

Combination therapies to improve the efficacy of immunotherapy in triple-negative breast cancer [RNA-seq]

2023-08-15 | GSE229422 | GEO

Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy [scRNA-Seq]

2026-01-30 | GSE305842 | GEO

Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy

Project description:Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy

| PRJNA1307634 | ENA

Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy [scRNA-Seq]

Project description:Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy [scRNA-Seq]

| PRJNA1308006 | ENA

Neo-Adjuvant Oncolytic Virotherapy Prior to Surgery Sensitizes Triple-Negative Breast Cancer to Immune Checkpoint Therapy

Project description:Neo-Adjuvant Oncolytic Virotherapy Prior to Surgery Sensitizes Triple-Negative Breast Cancer to Immune Checkpoint Therapy

| PRJNA413701 | ENA

Blocking Fra-1 sensitizes triple-negative breast cancer to olaparib

Project description:Blocking Fra-1 sensitizes triple-negative breast cancer to olaparib

| PRJNA629373 | ENA

Neo-Adjuvant Oncolytic Virotherapy Prior to Surgery Sensitizes Triple-Negative Breast Cancer to Immune Checkpoint Therapy

Project description:Triple-negative breast cancer (TNBC) is an aggressive disease for which treatment options are limited and associated with severe toxicities. In this experiment we evaluated the response of 2 murine TNBC models to oncolytic Maraba virus infection.

2018-10-01 | GSE104737 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data